Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that it has received US Food and Drug Administration (FDA) approval for Gazyva (obinutuzumab) to treat adults with primary membranous nephropathy (pMN) at risk of disease progression, making it the first and only approved treatment for the condition.
The approval is based on Phase III MAJESTY trial results, which showed that 36.1% of patients receiving Gazyva achieved complete remission of proteinuria after two years, compared with 5.7% for tacrolimus. Overall remission rates were 50% and 12.9%, respectively, with no new safety signals identified.
Primary membranous nephropathy is a rare, chronic autoimmune disease that can cause irreversible kidney damage and progress to kidney failure.
This approval marks Gazyva's third FDA authorisation in immune-mediated kidney diseases, following previous approvals for idiopathic nephrotic syndrome and lupus nephritis. The FDA is also reviewing Gazyva for systemic lupus erythematosus, with a decision expected by December 2026, while a European regulatory decision is anticipated following a positive recommendation from the CHMP.
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
argenx reports positive Phase 2 results for FB102 in coeliac disease
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
Abogen enters Novartis licensing and option agreement to advance RNA programs
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis